Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$DCLT, $GNPT, $SURE, $VGID & $COBI: could be the next 10-50x bagga!
$CHRO: Smart Home Sector Could Be Worth Hundreds Of Billions In Next Five Years
A new report suggests that ‘smart’ homes could be one of the next major markets to take off. Deutsche Telekom (DT), a German telecommunications company, has released a report that, it says, demonstrates the potential of the sector, the hurdles it must over-come to reach that potential and the opportunities it can afford to new and established businesses.
DT predicts that 100 million households will be ‘smart’ across the globe by the end of the year and this will increase to 300 million over the next ten years. Building on other companies’ analyses, DT expects to see consumer spending on smart home products and services to hit €90.90 billion globally by 2018 and accelerate from there to €122.77 billion by 2020.
It adds that Strategy Analytics, a market research firm, claims that the home market in the EU could be worth over €15.46 billion annually by 2019, with 50 million Western European homes having installed smart home technology.
Clearly there is some money to be made in the area. But what is involved in the nebulous terminology of ‘smart’ homes – also sometimes referred to as the Internet of Things – and what role do entrepreneurs have to play in it?
Put simply, a ‘smart’ home is one that is inter-connected for communication – either between various automated devices in the house or to an off-site location. This can take many forms and perform numerous functions. Homes can be designed and built with wiring and equipment in place for this purpose, alternatively inter-connected systems can be bought and installed in older dwellings. Individual devices can also be bought and added in ad hoc to eventually become some sort of smart system.
The purpose of these systems or individual pieces can be myriad. Typically current ‘smart’ devices revolve around entertainment, security or energy efficiency. These include relatively well known examples such as Chromecast ‘smart’ TV adapter, the Nest thermostat and the Dropcam home monitoring system (both now part of the Google GOOGL +0.80%/Alphabet empire).
http://www.forbes.com/sites/freddiedawson/2015/09/30/smart-home-sector-could-be-worth-hundreds-of-billions-in-next-five-years/#5e786e3b499c
- Go CHRO
$CHRO: Short term...Midterm & Long-term...They're all "Strong Buy"!
- Go CHRO
***** $CHRO: A new beginning will start from this pt. on~ 'The Chron Organization Inc. (CHRO)' ...a new name, a ticker...N new PPS high~ n very soon...a new group of traders...whales/sharks/dolphins will come & the sky is the limit! $.25 cents imminent! *****
- Go CHRO
$CHRO: Gonna F up Motherflower Inbred Trolls n Stinky-wild Leprechauns
Check out $IFLM ....Huge bids and no dilution........great DD on the board......z
***** $CHRO: could run like TT** (II), MG* (T), CG**(RW), etc. from $.00x or for low $.0x to $1.00s+ *****
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122551963
$SURE, $COBI, $LUSI, $GNPT, $VGID: Super thin...take little to get to mid $.00x range
$PMCB PharmaCyte Biotech’s Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
SILVER SPRING, Md., April 25, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte’s biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte’s pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.
Dr. Steven Chamow of Chamow & Associates stated, “Use of the live-cell encapsulation technology is very complex with many manufacturing steps and processes. GMP readiness of a biologic manufacturing facility such as the Bangkok site is no exception. In a relatively short period of time, with the relentless and determined cooperation we received from Austrianova, the facility is ready for GMP manufacture to produce the encapsulated cells that are a major part of PharmaCyte’s pancreatic cancer therapy.”
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are delighted to announce this exciting milestone in the development of our therapy for pancreatic cancer. This is a major step in generating the overall Chemistry, Manufacturing and Controls (CMC) information, which makes up a large part of the pre-IND package we will be submitting to the U.S. Food and Drug Administration (FDA). We would like to thank Chamow & Associates and Austrianova for completing this process. With the facility ready for cGMP manufacture, we are now in a position to engage with the FDA to discuss our clinical investigational plan and initiate our first clinical trial.”
Over the last few months, following an initial on-site audit of the facility by Chamow & Associates, numerous detailed documents were required to be prepared, reviewed and approved by Chamow. These documents include the quality management system manual and a variety of facility-related standard operating procedures (SOPs). In addition, all facility-related equipment has successfully completed the necessary Installation Qualifications (IQ) and Operational Qualifications (OQ).
Dr. Brian Salmons, the Chief Executive Officer of Austrianova, said, “We are exceedingly pleased that we were able to have our unique state-of-the-art live-cell encapsulation facility assessed as ready for GMP manufacture by Chamow & Associates. Both of the teams from Austrianova and Chamow worked together seamlessly and virtually nonstop to ensure that the facility is ready for GMP manufacture of PharmaCyte’s biologic product. We did so to enable PharmaCyte to reach the clinic with its novel therapy for pancreatic cancer at the earliest opportunity.”
The Austrianova facility will be used to encapsulate the genetically engineered live human cells that, together with low doses of the cancer prodrug ifosfamide, make up PharmaCyte’s pancreatic cancer therapy. PharmaCyte’s cancer therapy attacks the pancreas tumor with “targeted chemotherapy,” resulting in significant tumor shrinkage, the ability to convert some tumors from inoperable to operable, a reduction in the pain associated with the disease and an improvement to a patient’s overall quality of life.
PharmaCyte’s upcoming clinical trial in advanced inoperable pancreatic cancer involves placing the genetically modified live cells near the blood supply to the pancreas. The cancer prodrug ifosfamide is then given at one-third the normal dose. The prodrug is converted to its active form at the site of the tumor. In an earlier Phase 1/2 clinical trial, this “targeted chemotherapy” demonstrated far greater efficacy than the then “gold-standard” of care with no meaningful side-effects from the chemotherapy. Patients enrolled in PharmaCyte’s clinical trial will have non-metastatic, locally advanced and inoperable pancreatic cancer. They will be eligible for the trial if their tumors are either stable or progressing after 4-6 cycles of treatment with either of the two most commonly used chemotherapies for these cancers – the two-drug combination of Abraxane® plus gemcitabine or the four-drug combination known as FOLFIRINOX. PharmaCyte’s therapy will be compared in such patients with the current “standard of care,” which consists of the combination of the anticancer drug capecitabine plus radiation.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. The encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated live cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte and its future events and results that involve inherent risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
http://investingnews.com/daily/life-science-investing/biotech-investing/pharmacyte-biotechs-live-cell-encapsulation-facility-commissioned-gmp-manufacture/
$CHRO, $MFST, $DCLT: Super Hot & Super thin!
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$DCLT, $MFST, $UPZS: $.00x-.x play
$CHRO: Look at the chart and you can see $.05-.10 is imminent~
$COBI: Chart says reversal starting.
Drugdoctor's-Fablous-March-WINNERS-Chart-Updates-$PXYN-$GRNH-$CGRW
$PXYN - sitting on a double but much more to come as we expect NET PROFITS for ANNUAL REPORT to be announced this week!
$GRNH - What more can you say about a stock that is more than double and volume is skyrocketing on blowout earnings?
Finally $CGRW - Multi-Dollar Potential here...
Anyone remember 2014 MMJ stock boom? CGRW and GRNH - real players in the MMJ field... $PXYN - already blowing out revenues and NET PROFITS... This is a Trifecta folks!
$CHRO: Remember CHRO could be more wild than a Horny, raging-breeding bull~ With some cough-syrup & without parental supervision...she could be like some teenager (girl) or confused-young boy trying to hump Justin Bieber @ Music festival or concert!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121072071
Stop shorting & Cover, treat this 'tch (USAR) with respect & you could have "Whatever You Like"!
Check out $CHRO long-term chart (5 yrs chart):
Party just starting~ $.05-.10 Imminent!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121138431
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121296399
Don't forget the chance of seeing a "Huge" Short-Squeeze here! Big Win! Big $$$ for everyone!!!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121182772
$CHRO: My POS DD (read it & one will see why CHRO is undervalued):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121420687
- Go CHRO
$DCLT great share structure and a real software company!
$DCLT, $IPRU, $MFST, $UPZS, $GBSN: $.00x-.x play
$SFOR, $SWHI, $SDVI, $SURE, $SEWC: $.0001-.0009
Attention "NO BRAINERS" Players! Want to make BIG $$$ 10x-300x BAGGAS? Then click "FOLLOW BOARD" below & sign up for our Chairmail Subscription. Follow us to win BIG $$$:
Chairmail Subscription
http://investorshub.advfn.com/boards/chairmail_sub.asp?board_id=7874
$CHRO Mini DD: CHRO could be like "Diversegy" & "Genie Energy share [Symbol: GNE / ISIN: US3722842081]"
Something that the President of this co. is associated with~
https://twitter.com/nrgneversleeps/status/701127580586348544
https://www.linkedin.com/in/legendsenergy
GNE, which he has been managing is a NYSE stock~ trading at $9.20 cents~
http://www.quotenet.com/stock-price/GNE
https://www.facebook.com/diversegy/
"$CHRO This Share Price is Peanuts for Alex Rodriguez he has built & worked BILLION $$$ Companies. Read his BIO on Bloomberg once. This stock is going way past 01! "
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120787105
http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=252714454
See this video:
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
$MFST: could become a dollar stock!
$GNPT was a low of .0005 We now sit at .0011 we are a 10 bagger
http://finance.yahoo.com/q/ks?s=GNPT+Key+Statistics
ATLANTA, GA / ACCESSWIRE / January 14, 2015 / GreenParts International, Inc. (OTC: GNPT) a diversified recycling company based in Atlanta, Ga, has successfully completed a $5 million dollar long-term refinance package at a current rate of 6.25 %. This reduces the Company's average rate of debt service by approximately 75%.
Asif Balagmwala, Greenparts CEO, commented, "This improved financing is a direct result of our team's diligence in adapting to our industry's changing market conditions. The closing of this million dollar loan at just a few points over prime, marks a significant and necessary milestone achievement in the implementation of our strategic plan. We have always recognized the need to reduce our debt to a manageable level. In addition to reducing our interest costs, we have also decreased our short-term debt by over $500,000 dollars, a figure that is just over 10% of our total debt."
Additionally, the loan facilitated GreenParts making two new property acquisitions with an asset value of $2,500,000.
Balagmwala concluded, "I'm very encouraged by our progress in this successful debt consolidation. It enables us to focus on stabilizing cash flow and strengthening our core business. While we continue efforts to further reduce debt load, we are now implementing other key elements of our strategic plan including continued acquisitions and increased investment in diversification efforts. I'm excited for the opportunities I see in 2016. I know that by remaining steadfast in our commitment to the GreenParts strategic plan, we will enjoy success at every level."
8-K will hit GNPT http://www.otcmarkets.com/stock/GNPT/news
Additionally, the loan facilitated GreenParts making two new property acquisitions with an asset value of $2,500,000.
OUR ASSETS ARE NOW 10 MILLION ABOUT AND GROWING
Hi $GNPT is expanding as stated ,yes increased AS so financing could be established, 5 MILLION done..... http://www.otcmarkets.com/stock/GNPT/news
Jan 14, 2016 Greenparts International Reduces Debt Service Cost By 75% ACCESSWIRE
Dec 24, 2015 GreenParts International Inc. Announces Increased Share Authorization ACCESSWIRE
Nov 16, 2015 Green Parts International Returns To Profitability In Third Quarter
LPPI looks like they had a good day in court today.
We should get Praxsyn earnings after close Monday 11/16/15! $PXYN
$$DSUS$$Here is a kinda MASTER DD post below starting with some videos of products in operation then some info on "THE PRODROPPER" and at the end DD NOTES lots of VERY VERY POSITVE happenings with $$DSUS$$ only could lead to lots of $$$$$$$$$!!!!!
1ST PROTOTYPE SAR SPOTLIGHT VIDEO!!!
$PXYN came to life today!
ASTI going for another round here - a little shaky.
GBSN - waiting for the force feeding to stop. There is a max to the warrant dilution, getting close to it.
And - once again - a NOBRAINER Confirmed! I caught ASTI this time... picked em up .23 and sold in high .30's..... I'm out again, lol... Amazing play... Thanks again for the pick!
**IGRW** on HIgH alert!!!! 26 million cross trade. BKRT and VNDM moved wayyyy back right after it
Yea, I let the debt structure scare me out of ASTI with just a nice pop... Looking for bridge or something high to jump off of for missing this one.... lol.... GREAT NOBRAINER CALL!
ASTI calling for NO BRAINER (again) from .21 close last night. Chart shows lots of room to go.
It just hit .18 - Incredible.... I left a lot of $$$$ on the table, but I'm still happy, lol.... What a short squeeze today!
Followers
|
409
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
10176
|
Created
|
12/31/06
|
Type
|
Free
|
Moderator Drugdoctor | |||
Assistants kermit42 MaxPowerLove$Ihub |
WELCOME to the NOBRAINERS BOARD
NO BRAINER HALL OF FAME!!!
ICNB.0305 Iconic Brands up 1900% picked by Drugdoctor on 12/21/16 at .0016 SMKY-Smokey Market Foods, Inc up 3650%..............Picked by DOLLARLAND on 3/9/11 at .012 GOIG-GOIP Global Inc - up 2150% ……………………………Picked by TurtleBK on 2/5/10 | ||||||||
ISML- ISM International - up 633%...................Picked by DOLLARLAND on 9/15/11 at .03 | ||||||||
FRHV- Fresh Harvest Products - up 502%...................Picked by Bliz82 on 3/13/10 | ||||||||
WDRP-Wanderport Corp - up 1054% …………………………..Picked by Burntwood on 2/1/10 | ||||||||
CCTC-Clean Coal technologies - up 733%....................Picked by Daytrader2008 on 2/15/10 | ||||||||
DLCR-David Loren Corp - up 500% ………………………………..Picked by creppie on 1/1/10 | ||||||||
AAGH - Asia Global Holdings, peaked up 608.16% ......................Picked by Charlatan on 2/13/07 | ||||||||
AMPE/HVAE - High Velocity Alternative Energy, peaked up 519%....................Picked by Obi_Penny_Kanobi on 08/09/07 | ||||||||
ATLJ - Asia Telecom, Ltd peaked at 804.76%........................Picked by pop-a-top on 01/19/07 | ||||||||
COPI - Compliance Systems up 2310% .........................Picked by kermit42 on 08/27/07 at .0039 | ||||||||
DPDW -- Deep Down Inc. peaked at 980%..................Picked by brikk on 1/1/07 | ||||||||
EESO --Enzyme Environmental Soln. up 3900% - picked by burp on 03/26/08 at .0007 | ||||||||
HMGP - Hemi Energy Group Inc. peaked at 505% ...................Picked by lowman on 01/01/07 | ||||||||
PDGT - Paradigm Tactical Products, Inc. up 500%........................picked by kraigger23 on 5/6/07 | ||||||||
SRSR - Sarissa Resources - up 12,352% picked by AngieM on 11/12/07 | ||||||||
```````````NO BRAINERS`````````````
The buzzwords of the 1990's - Rocket Ride - Train Leaving the Station - BACK UP THE TRUCK, LOAD THE BOAT, TO da MOON! Well, the 2010's are finally here, and THE NO BRAINERS are back!
All NASDAQ, OTCBB, and PINKIES are welcome, but please keep the price below $5 because we are looking for at least 50% gains on any pick posted! Also, the gain must occur within 6 months of the date posted! Let's not pick any stocks below .0005 because just the spread is 50% in a lot of cases. Also, if your pick retraces 25% after posting, it becomes a LAME BRAINER, and your pick is off the board.
So please - Post your NO BRAINER - but post your reason also. Please post the closing price. If you post a NOBRAINER while the market is open, come back and post the closing price please! Also, post a chart, and any other supporting links will be nice.
HOW TO POST A CHART IN A MESSAGE!
If you want to know how to show a chart in a post, here are the instructions, but PLEASE use the test board before posting here!
http://www.investorshub.com/boards/read_msg.asp?message_id=16557615
Use this link for a nice quick 3 month chart...
http://stockcharts.com/h-sc/ui?s=wegi&p=D&yr=0&mn=3&dy=0&id=p89527042396
If you think SIRI is finally going to post profits and the price will explode up over 50% from where it is now, then put it on the board. What we will try to do, is evaluate the suggestions and put the picks, the date, the price, and the poster name in the I-box.
So pick away, but remember, your picks will be here for all to see!!!
http://investorshub.advfn.com/boards/board.aspx?board_id=18435
"A Dawgg"
http://investorshub.advfn.com/boards/board.aspx?board_id=21519&NextStart=20
Watchlist
LAMEBRAINERS - in timeout - you can't pick these for awhile - they have failed the NOBRAINER test----
INIA
Please give feedback.
NOBRAINER INFO SECTION
NOBRAINERS Charts!
PRAXSYN Pharma
ELTP -ELITE Pharmaceutical
Disclaimer: These are penny stocks, very risky, and you may lose all your money if you invest in any NOBRAINER mentioned above. Also, we may trade in and out of any of the above securities at any time and without notice.
Posts Today
|
0
|
Posts (Total)
|
10176
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |